The ZEISS Group had a very successful end to the first six months of fiscal year 2016/17 (ended 31 March) and saw its revenue rise by 10 percent to EUR 2.550 billion (1st half of 2015/16: EUR 2.322 billion). At EUR 384 million, the earnings before interest and tax (EBIT) were significantly ... more
World Finance 100 Award for Carl Zeiss MicroscopyThe Carl Zeiss Microscopy business group is one of the world's 100 financially most successful companies
The Carl Zeiss Microscopy business group has received the World Finance 100 Award for its financial performance in 2011, presented by the British financial magazine World Finance. In fiscal year 2010/11 the Microscopy business group generated revenue totaling EUR 423m. This corresponds to an increase of EUR 26m – or seven percent – over the prior year (EUR 397m). During the reporting period Carl Zeiss Microscopy won an additional market share in almost all markets – both with microscopes for biomedical research and with systems for materials microscopy in industry. The business group achieved particularly strong growth in Latin America, Asia and Europe. The fusion of light and electron microscopy into a single business group started in the fiscal year 2010/11 and makes Carl Zeiss Microscopy the only one-stop provider for the whole portfolio of microscopy.
"We are proud of receiving this award and are delighted that our financial success has earned global recognition. A solid financial foundation enables us to also achieve top performance in the fields of science and technology in the future," says Dr. Ulrich Simon, Executive Vice President of the Microscopy business group.
The British financial magazine World Finance presents this award to the world's 100 financially most successful organizations and individuals every year. Not only financial criteria, but also innovativeness, sustainability and corporate image all play an important role in the jury's decision.
A new agreement between the Carl R. Woese Institute for Genomic Biology (IGB) at the University of Illinois at Urbana-Champaign and ZEISS has named the Core Facilities at IGB as an official ZEISS labs@location Partner. The model facility will allow researchers from around the U.S. to test-d ... more
The patent protects a special aphakic intraocular lens (IOL), with which light can be focused on three focal points (near, intermediate and distance vision). The patented trifocal lens reduces the impact of pupil shrinkage and lens eccentricity. VSY Biotechnology BV and its exclusive suppli ... more
- 1Potential cause for lupus identified
- 2Why do BRCA1 mutations cause predominantly breast and ovarian cancer?
- 3Peptide complex formed in the brain is responsible for Alzheimer's disease
- 4LUM incorporates subsidiary in the Land of the rising sun
- 5Personalize your medication dosages
- 6The proton precisely weighted